Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
暂无分享,去创建一个
[1] M. Beckmann,et al. Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .
[2] Trevor J Pugh,et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.
[3] J. Qi,et al. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). , 2015, Pharmaceutical patent analyst.
[4] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] Li Ma,et al. The emerging molecular machinery and therapeutic targets of metastasis. , 2015, Trends in pharmacological sciences.
[6] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[7] L. Maher,et al. Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma , 2015, PloS one.
[8] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[9] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[10] Richard L Schilsky,et al. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[12] T. Bestor,et al. Notes on the role of dynamic DNA methylation in mammalian development , 2014, Proceedings of the National Academy of Sciences.
[13] M. Beksac,et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. , 2014, The Lancet. Oncology.
[14] S. Grant,et al. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. , 2014, Pharmacology & therapeutics.
[15] S. Baylin,et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes , 2014, Oncogene.
[16] J. Herman,et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Solter,et al. DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos , 2014, Genes & development.
[18] Gang Wu,et al. Histone H3 mutations in pediatric brain tumors. , 2014, Cold Spring Harbor perspectives in biology.
[19] E. Seto,et al. Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.
[20] Peter A. Jones,et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.
[21] R. Johnstone,et al. New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.
[22] S. Baylin,et al. Harnessing the potential of epigenetic therapy to target solid tumors. , 2014, The Journal of clinical investigation.
[23] M. Gilbert,et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Y. Schwartz,et al. A new world of Polycombs: unexpected partnerships and emerging functions , 2013, Nature Reviews Genetics.
[25] Peter A. Jones,et al. Alterations of immune response of non-small cell lung cancer with Azacytidine , 2013, Oncotarget.
[26] Pu Zhang,et al. DNMT1-interacting RNAs block gene specific DNA methylation , 2013, Nature.
[27] S. Sleiman,et al. Epigenetics of Alzheimer’s Disease and Frontotemporal Dementia , 2013, Neurotherapeutics.
[28] William A. Pastor,et al. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription , 2013, Nature Reviews Molecular Cell Biology.
[29] Bohuslav Melichar,et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Zahnow,et al. The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.
[31] M. Millan. An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy , 2013, Neuropharmacology.
[32] Marco A. Marra,et al. Cancer genome-sequencing study design , 2013, Nature Reviews Genetics.
[33] J. Huse,et al. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. , 2013, Journal of neuropathology and experimental neurology.
[34] Peter W. Laird,et al. Interplay between the Cancer Genome and Epigenome , 2013, Cell.
[35] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[36] A. H. Smits,et al. Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives , 2013, Cell.
[37] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.
[38] Jeannie T. Lee. Epigenetic Regulation by Long Noncoding RNAs , 2012, Science.
[39] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[40] Tim J. Wigle,et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.
[41] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[42] Peter A. Jones,et al. Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.
[43] M. Dawson,et al. Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.
[44] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[45] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[46] H. Hock. A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.
[47] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[48] Nita Ahuja,et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.
[49] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[50] M. Esteller,et al. Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.
[51] Martin Renqiang Min,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[52] J. Uhm. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .
[53] F. Rassool,et al. HDAC inhibitors: roles of DNA damage and repair. , 2012, Advances in cancer research.
[54] J. Herman,et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.
[55] Peter A. Jones,et al. A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.
[56] Yonghong Xiao,et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.
[57] G. Mufti,et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.
[58] R. Bast,et al. Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.
[59] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[60] Peter A. Jones,et al. Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.
[61] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[62] K. Helin,et al. Polycomb group protein-mediated repression of transcription. , 2010, Trends in biochemical sciences.
[63] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[64] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[65] Peter A. Jones,et al. S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth , 2010, Molecular Cancer Therapeutics.
[66] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[67] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[68] C. Caskey. Using genetic diagnosis to determine individual therapeutic utility. , 2010, Annual review of medicine.
[69] M. Maitland,et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Kristian Helin,et al. Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.
[71] M. Gobbi,et al. Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes , 2009, Clinical Cancer Research.
[72] A. Shilatifard,et al. An operational definition of epigenetics. , 2009, Genes & development.
[73] G. Garcia-Manero. Demethylating agents in myeloid malignancies , 2008, Current opinion in oncology.
[74] A. Feinberg,et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA , 2008, Nature.
[75] T. Tomasi,et al. Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.
[76] R. Schneider,et al. Dynamics and interplay of nuclear architecture, genome organization, and gene expression. , 2007, Genes & development.
[77] S. Berger. The complex language of chromatin regulation during transcription , 2007, Nature.
[78] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[79] J. Herman,et al. Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage. , 2006 .
[80] P. Pandolfi,et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome , 2006, Leukemia.
[81] H. Clevers. Wnt/beta-catenin signaling in development and disease. , 2006, Cell.
[82] G. Mufti,et al. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome , 2005, Nature Clinical Practice Oncology.
[83] J. Issa. DNA methylation in the treatment of hematologic malignancies. , 2005, Clinical advances in hematology & oncology : H&O.
[84] K. Ghoshal,et al. 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.
[85] Richard Pazdur,et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.
[86] Wei Dong Chen,et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.
[87] David A Jones,et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.
[88] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Keith D Robertson,et al. DNA methylation, methyltransferases, and cancer , 2001, Oncogene.
[90] M. Lübbert,et al. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.
[91] J. Herman,et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.
[92] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[93] Peter A. Jones,et al. Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.